Study of the Efficacy of Oxfendazole Compared to Albendazole in the Treatment of Trichuris Trichiura Infection in Adults

Sponsor
Johns Hopkins Bloomberg School of Public Health (Other)
Overall Status
Withdrawn
CT.gov ID
NCT02636803
Collaborator
Universidad Peruana Cayetano Heredia (Other)
0
4
15

Study Details

Study Description

Brief Summary

The aim of this study is to provide data on the efficacy of oxfendazole against Trichuris trichiura at different doses in comparison to the standard single 400 mg dose of albendazole. In addition, the study will provide data on oxfendazole efficacy against other common nematodes encountered in man (Enterobius vermicularis, Ascaris lumbricoides, Ancylostoma duodenalis, Necator americanus).

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

This is an open, comparative study in adult patients with proven intestinal infection with Trichuris trichiura. Patients meeting the study entry criteria will receive either 6mg/kg, or 30 mg/kg of oxfendazole as a single oral dose or 6 mg/kg orally for three days or albendazole 400mg as a single oral dose. Stool samples will be obtained and examined 7, 14 and 21 days after treatment.

Two hundred clinically evaluable patients of either gender, 16 - 65 years of age, presenting with proven Trichuris trichiura infection, recruited from one centre, will be included in the study. there will be 15 patients in each treatment group. Duration of accrual will be determined in discussion with the clinical site in Iquitos, Peru.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Factorial Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
An Open Comparative Study of the Efficacy of Different Doses of Oxfendazole Compared to Single Dose Albendazole in the Treatment of Trichuris Trichiura Infection in Adults
Anticipated Study Start Date :
Nov 1, 2019
Anticipated Primary Completion Date :
Aug 1, 2020
Anticipated Study Completion Date :
Feb 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: oxfendazole 6 mg/kg

patients receive 6 mg/kg oxfendazole once

Drug: oxfendazole
group receives a single dose of oxfendazole at 6 or 30 mg/kg or three 6 mg/kg doses

Experimental: oxfendazole 30 mg/kg

patients receive 30 mg/kg oxfendazole once

Drug: oxfendazole
group receives a single dose of oxfendazole at 6 or 30 mg/kg or three 6 mg/kg doses

Experimental: oxfendazole 6 mg/kg 3 times

patients receive 6 mg/kg oxfendazole three times

Drug: oxfendazole
group receives a single dose of oxfendazole at 6 or 30 mg/kg or three 6 mg/kg doses

Active Comparator: albendazole 400 mg

patients receive 400 mg albendazole once

Drug: albendazole
group receives one 400 mg dose of albendazole

Outcome Measures

Primary Outcome Measures

  1. Cure of Trichuris trichiura [day 21 following treatment]

    Cure of infection (Clinical Cure) shown by absence of Trichuris eggs in stool examinations at Day 21, using Kato Katz test.

  2. Reduction in Trichuis trichiura eggs (compared to pretreatment) [day 21 following treatment]

    Reduction (compared to baseline) of Trichuris eggs in stool examinations at 21, using Kato Katz test.

Secondary Outcome Measures

  1. Cure of other intestinal helminths [day 21 following treatment]

    Absence of Ascaris, Necator eggs in stool using Kato Katz test

  2. Safety and tolerability of oxfendazole in the treatment of adult patients assessed by cumulative adverse events [treatment through day 21 following treatment]

    Cumulative adverse events following treatment up to Day 21

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Written or witnessed oral informed consent has been obtained.

  2. Has Trichuris trichiura demonstrated in stool samples obtained during the week before enrolment: The presence of other helminths: Enterobius vermicularis, Ascaris lumbricoides, Necator americanus, Ancylostoma duodenalis will not be a cause for exclusion.

  3. Is willing to comply with the requirements of the protocol and particularly to provide 4 stool samples, pretreatment and 7, 14 and 21 days after treatment.

  4. Female patients of child bearing potential, who are using an established method of birth control (surgically sterile, intra-uterine contraceptive device, oral contraceptives, diaphragm in combination with contraceptive cream or foam, or condom in combination with contraceptive cream or foam)

Exclusion Criteria:
  1. The patient has demonstrated a previous hypersensitivity reaction to benzimidazole or other related compound.

  2. Presence of other helminths without Trichuris trichiura. Note: Non-target species may be present and details of response will be recorded.

  3. The patient has diarrhoeal disease that would interfere with the evaluation of stool samples.

  4. The patient has received an anthelminthic in the 2 weeks prior to enrolment into the study.

  5. The patient has received an investigational drug within 30 days or 5 half-lives (whichever is longer) of the screening visit or is scheduled to receive such a drug during the study period.

  6. The patient has a concomitant infection or any other underlying disease that would compromise the diagnosis and the evaluation of the response to the study medication.

  7. The patient has a known history of renal dysfunction (plasma creatinine ≥ 1.5 times upper limit of normal for age) or hepatic dysfunction (liver enzymes ≥ 1.5

  8. Is a female who is pregnant, lactating or planning a pregnancy during the study, or is not practicing any form of contraception (see inclusion criteria (4.2.5).

  9. Patient that is unwilling or unable to take part in this study.

  10. The patient has previously been enrolled in the study.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Johns Hopkins Bloomberg School of Public Health
  • Universidad Peruana Cayetano Heredia

Investigators

  • Principal Investigator: Robert H Gilman, MD, Johns Hopkins Bloomberg School of Public Health
  • Principal Investigator: Hector H Garcia, MD, PhD, Universidad Peruana Cayetano Heredia
  • Principal Investigator: Richard J Horton, MB BChir, MRCGP, FFPM, Tropical Projects
  • Principal Investigator: Armando E Gonzalez, DVM, PhD, National University of San Marcos, Peru

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Johns Hopkins Bloomberg School of Public Health
ClinicalTrials.gov Identifier:
NCT02636803
Other Study ID Numbers:
  • OXF2
First Posted:
Dec 22, 2015
Last Update Posted:
Aug 15, 2019
Last Verified:
Aug 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Johns Hopkins Bloomberg School of Public Health
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 15, 2019